Log in

NASDAQ:IRWDIronwood Pharmaceuticals Stock Price, Forecast & News

$9.87
-0.23 (-2.28 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.50
Now: $9.87
$10.26
50-Day Range
$8.58
MA: $11.02
$13.07
52-Week Range
$7.91
Now: $9.87
$14.10
Volume1.25 million shs
Average Volume2.10 million shs
Market Capitalization$1.56 billion
P/E Ratio75.93
Dividend YieldN/A
Beta1.75
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Read More
Ironwood Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$428.41 million
Cash Flow$0.56 per share
Book Value($0.59) per share

Profitability

Net Income$21.50 million

Miscellaneous

Employees515
Market Cap$1.56 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.


Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

How has Ironwood Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ironwood Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IRWD shares have decreased by 6.0% and is now trading at $9.87. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ironwood Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ironwood Pharmaceuticals.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Ironwood Pharmaceuticals.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Thursday, February, 13th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.22 by $0.08. The biotechnology company had revenue of $126.30 million for the quarter, compared to the consensus estimate of $112.06 million. Ironwood Pharmaceuticals had a net margin of 5.02% and a negative return on equity of 46.52%. The firm's quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.02) earnings per share. View Ironwood Pharmaceuticals' earnings history.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $360-380 million, compared to the consensus revenue estimate of $391.25 million.

What price target have analysts set for IRWD?

6 analysts have issued twelve-month price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $14.00 in the next year. This suggests a possible upside of 41.8% from the stock's current price. View analysts' price targets for Ironwood Pharmaceuticals.

Has Ironwood Pharmaceuticals been receiving favorable news coverage?

News headlines about IRWD stock have been trending very negative recently, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutIronwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Micron Technology (MU), Allergan (AGN), Aegean Marine Petroleum Network (ANW) and Continental Resources (CLR).

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the following people:
  • Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
  • Mr. Thomas A. McCourt, Pres (Age 62)
  • Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
  • Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
  • Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel.

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View institutional ownership trends for Ironwood Pharmaceuticals.

Which institutional investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Ironwood Pharmaceuticals.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $9.87.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $1.56 billion and generates $428.41 million in revenue each year. The biotechnology company earns $21.50 million in net income (profit) each year or $0.55 on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe. View additional information about Ironwood Pharmaceuticals.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: Analyst Ratings Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel